Celgene

Celgene taps Bristol-Myers salesforce to bolster key blood cancer launches
Celgene taps Bristol-Myers salesforce to bolster key blood cancer launches
Fierce Pharma
Celgene
Bristol-Myers Squibb
blood cancer
Flag link:
JPM: Bristol chief says one-third of Celgene cost cuts will hit in 2020
JPM: Bristol chief says one-third of Celgene cost cuts will hit in 2020
Fierce Pharma
M&A
JPMHC 2020
Bristol-Myers Squibb
Celgene
Giovanni Caforio
Flag link:
Bristol-Myers confident of approvals linked to higher Celgene investor payout: Bristol executive
Bristol-Myers confident of approvals linked to higher Celgene investor payout: Bristol executive
Reuters
Bristol-Myers Squibb
Celgene
M&A
liso-cel
ozanimod
bb2121
FDA
Flag link:
Bristol-Myers unloads old-school plant as it readies for CAR-T future
Bristol-Myers unloads old-school plant as it readies for CAR-T future
Fierce Pharma
Bristol-Myers Squibb
Celgene
CAR-T
M&A
Flag link:
Celgene-Seeded PharmAkea Sells Last Fibrotic Drug Candidate to Galecto
Celgene-Seeded PharmAkea Sells Last Fibrotic Drug Candidate to Galecto
Xconomy
Amira Pharmaceuticals
Bristol-Myers Squibb
Celgene
PharmAkea
Galecto Biotech
fibrotic disease
Flag link:
Top Biopharma M&As in 2019
Top Biopharma M&As in 2019
BioSpace
M&A
Bristol-Myers Squibb
Celgene
AbbVie
Allergan
Roche
Spark Therapeutics
Novartis
The Medicines Company
Alkermes
Rodin Therapeutics
Sumitomo Dainippon
Roivant
Flag link:
How Gilead Sciences Is Helping Fund Bristol-Myers Squibb's Celgene Acquisition
How Gilead Sciences Is Helping Fund Bristol-Myers Squibb's Celgene Acquisition
Motley Fool
Bristol-Myers Squibb
Celgene
M&A
Flag link:
After big M&A year, will pharma move away from massive deals in 2020?
After big M&A year, will pharma move away from massive deals in 2020?
Fierce Pharma
M&A
Sanofi
Merck
AbbVie
Allergan
Bristol-Myers Squibb
Celgene
FTC
Flag link:
Bristol-Myers Placed A Big Bet On Celgene’s Pipeline. Will It Pay Off For Investors?
Bristol-Myers Placed A Big Bet On Celgene’s Pipeline. Will It Pay Off For Investors?
Motley Fool
Bristol-Myers Squibb
Celgene
M&A
Revlimid
patents
Flag link:
After Its Celgene Acquisition, Bristol-Myers Squibb's Future Looks Bright
After Its Celgene Acquisition, Bristol-Myers Squibb's Future Looks Bright
Motley Fool
Celgene
M&A
Bristol-Myers Squibb
Flag link:
Deal of the Year: Bristol-Myers Squibb buys Celgene
Deal of the Year: Bristol-Myers Squibb buys Celgene
Biopharma Dive
M&A
Bristol-Myers Squibb
Celgene
Flag link:
Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable
Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable
Motley Fool
Celgene
Editas Medicine
Juno Therapeutics
CRISPR
gene editing
Flag link:
BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MS
BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MS
Fierce Pharma
Bristol-Myers Squibb
Celgene
M&A
ozanimod
liso-cel
bb2121
Flag link:
Having gobbled up Celgene, the Bristol-Myers CEO ducks questions about his key rival
Having gobbled up Celgene, the Bristol-Myers CEO ducks questions about his key rival
Stat
Bristol-Myers Squibb
Celgene
Pharma CEOs
Giovanni Caforio
Merck
M&A
Flag link:
Amgen juices up sales outlook amid high hopes for Celgene castoff Otezla
Amgen juices up sales outlook amid high hopes for Celgene castoff Otezla
Fierce Pharma
Amgen
Otezla
Celgene
psoriasis
Flag link:
Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene
Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene
Pharmaceutical Business Review
M&A
Bristol-Myers Squibb
Celgene
Flag link:
AZ, Merck and Novartis top Big Pharma's Q3 growth charts. Teva and Pfizer? Not so much
AZ, Merck and Novartis top Big Pharma's Q3 growth charts. Teva and Pfizer? Not so much
Fierce Pharma
earnings
Big Pharma
AstraZeneca
Merck
Celgene
Novartis
Novo Nordisk
Pfizer
Flag link:
Bristol-Celgene Merger Leaps FTC Clearance; Deal Set To Close Wednesday
Bristol-Celgene Merger Leaps FTC Clearance; Deal Set To Close Wednesday
Investors Business Daily
Bristol-Myers Squibb
Celgene
FTC
M&A
Flag link:
Editas and Celgene sub Juno are tackling hottest immunotherapy cells
Editas and Celgene sub Juno are tackling hottest immunotherapy cells
Endpoints
Editas Medicine
Celgene
Juno Therapeutics
CRISPR
gene editing
immunotherapy
Flag link:
Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout
Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout
Biopharma Dive
ASH
Celgene
M&A
Bristol-Myers Squibb
liso-cel
Flag link:

Pages